SAB Biotherapeutics announces Phase 1 Clinical trial results for anti-MERS immunotherapy
Clinical stage biopharmaceutical company, SAB Biotherapeutics declared its phase 1 Clinical Trial results for treating MERS, a study that was undertaken by National Institutes of…
Read More...
Read More...